These approaches uncover functional niches, including androgen receptor–driven TNBC (LAR subtype) and immune-excluded claudin-low cancers, thereby expanding the repertoire of actionable biomarkers and revealing novel therapeutic vulnerabilities [145,162]. The gene discussed is AR; the disease is cancer.